Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation the Treatment Outcome of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University
• Treatments: Aspirin; Lamivudine

Criteria

Inclusion Criteria:

• Hepatocellular carcinoma confirmed with pathology or identified with radiological images with typical features

• Age ≥ 18 years and ≤ 75 years

• At least one tumor nodule with one uni-dimension of ≥ 2 cm

• Child-Pugh Class A or B

• HBV-DNA>10^4

• Total bilirubin ≤ 1.5 x upper limit of normal

• ALT and AST ≤ 2.0 x the upper limit of normal

• PT-INR<2.3,PTT < 1.5 x upper limit of normal

• Serum creatinine ≤ 1.5x upper limit of normal

• Peripheral white blood cell count of or more than 3×10(9)/L

• Peripheral platelet of or more than 50×10(9)/L

• Expected survival time not less than 3 months

• ECOG score 0-2

Exclusion Criteria:

• Tumor thrombi in main branch of portal vein

• Tumor involvement more than 70% of whole liver

• With extrahepatic metastasis

• Prior systemic chemotherapy or chemoembolization

• Congestive heart failure > NYHA class 2

• History of HIV infection

• Active clinically serious infections (> 2 NCI-CTC Version 3.0)

• Recurrence of HCC after liver transplantation

• Pregnant or breast-feeding

• Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in this study

• Known or suspected allergy to any agent given in association with this trial

• Patients unable to swallow oral medication

• Inclined to thrombosis

• Inclined to hemorrhage or active hemorrhage with 1 month